Peter Chin-Hong, MD

Phone: 415-502-9585
UCSF Box: 0654
Email: peter.chin-hong@ucsf.edu
UCSF Profile

Project Sponsor Location(s) Topics Start End
Sexual Behavior and HIV-1 Drug Resistance Bristol-Myers Squibb Company United States Substance Abuse
A Prophylactic Strategy Using Voriconazole vs. Inhaled Amphotericin to Prevent Invasive Aspergillosis in Lung Transplant Recipients Pfizer United States Infectious Disease, Opportunistic Infection, Chronic Respiratory Disease
Surveillance for Invasive Fungal Infections in Transplant Recipients: The Transplant Infections Network Duke University United States Surgery and Anesthesia
Human Papillomavirus as a Risk Factor for HIV Infection NIH National Institute of Allergy and Infectious Disease United States Infectious Disease, Sexually Transmitted Infections (STIs), HIV/AIDS
Deferasirox (Exjade)-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Los Angeles Biomedical Research Institute United States Opportunistic Infection, Drug and Diagnostics Development
A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants ViroPharma, Inc. United States Opportunistic Infection, Pharmacology and Drug Treatment
Protocol # ADMA-001: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial Evaluating the Safety and Efficacy of RI-001 in Medically Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV ADMA Biologics, Inc. United States HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment
Phase IV Open-Label, Non-comparative Trial of IV Anidulafungin followed by Oral Azole Therapy for the Treatment of Candidemia and Invasive Candidiasis Pfizer United States HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment
A8851009: A Prospective, Randomized Trial Comparing the Efficacy of Anidulafungin and Voriconazole in Combination to that of Voriconazole Alone When Used For Primary Therapy of Proven or Probable Invasive Aspergillosis Pfizer United States Opportunistic Infection, Pharmacology and Drug Treatment
Natural History and Outcomes of Coccidioidomycosis Retrospective Record Review Study University of California Davis United States Infectious Disease, Opportunistic Infection, Systematic Reviews and Guideline Development
Efficacy and Safety of Eraxis/Ecalta (Anidulafungin) Compared to Cancidas (Caspofungin) in Patients with Candida Deep Tissue Infection: A Phase 4 Study Pfizer United States Infectious Disease, HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment
WSA-CS-003: Open Label Study of Isavuconazole in the Treatment of Patients with Aspergillosis and Renal Impairment or of Patients with Invasive Fungal Disease Caused by Rare Molds, Yeasts or Dimorphic Fungi Astellas Pharma, Inc. United States Infectious Disease, Opportunistic Infection, Pharmacology and Drug Treatment
Phase III Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi Astellas Pharma, Inc. United States
Phase III Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections Astellas Pharma, Inc. United States Opportunistic Infection
Viral Pathogen Discovery in Opportunistic Infections in the Post-Transplant Setting Novartis Institute for BioMedical Research United States Infectious Disease, Opportunistic Infection, Surgery and Anesthesia
A Multicenter, Multinational, Retrospective Review of Voriconazole Experience for the Prophylaxis against Invasive Aspergillosis in Lung Transplant Recipients University of Toronto Canada Opportunistic Infection, Chronic Respiratory Disease